Výsledky vyhledávání - "Sanghun Iwashiro"

Akademický článek

Long-term safety of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: post-marketing extension surveillance in Japan

Autor: Makoto Arakawa, Yoshinori Ikeda, Hiromichi Otaka, Sanghun Iwashiro

Publikováno v: Molecular Genetics and Metabolism Reports, Vol 40, Iss , Pp 101122- (2024)

Fabry disease is a rare inherited X-linked metabolic disorder in which deficient alpha-galactosidase A activity causes progressive build-up of globotriaosylceramide (Gb3) and multi-system dysfunction. Following approval of agalsidase alfa for Fabry d

Externí odkaz: https://doaj.org/article/46005a26b2374345a6cd8785dc655334

Zobrazit plný text záznamu

Akademický článek

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)

Autor: Ikuo Fukuda, Atsushi Hirayama, Kazuo Kawasugi, Takao Kobayashi, Hideaki Maeda, Mashio Nakamura, Norifumi Nakanishi, Norikazu Yamada, Tsubasa Tajima, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki

Publikováno v: TH Open, Vol 05, Iss 04, Pp e521-e532 (2021)

Background The efficacy and safety of rivaroxaban have been demonstrated in phase 3 trials of patients with venous thromboembolism (VTE; pulmonary embolism [PE] and deep vein thrombosis [DVT]). Data regarding rivaroxaban treatment of VTE in routine J

Externí odkaz: https://doaj.org/article/313ff2ce01f142e49eb686e8b2f02342

Zobrazit plný text záznamu

Akademický článek

Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS.

Autor: Takanori Ikeda, Satoshi Ogawa, Takanari Kitazono, Jyoji Nakagawara, Kazuo Minematsu, Susumu Miyamoto, Yuji Murakawa, Sanghun Iwashiro, Yutaka Okayama, Toshiyuki Sunaya, Kazufumi Hirano, Takanori Hayasaki

Publikováno v: PLoS ONE, Vol 16, Iss 6, p e0251325 (2021)

BackgroundThe Xarelto Post-Authorization Safety and Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS) was designed to investigate safety and effectiveness during long-term follow-up of rivaroxaban treatment, using reduced dos

Externí odkaz: https://doaj.org/article/b4c49a7ceb404b83a60b6d9e87b35dea

Zobrazit plný text záznamu

Design and Baseline Data for a Prospective Observational Study of Rivaroxaban in Patients with Venous Thromboembolism in Japan (XASSENT)

Autor: Norifumi Nakanishi, Kazuo Kawasugi, Takao Kobayashi, Atsushi Hirayama, Ikuo Fukuda, Mashio Nakamura, Tsubasa Tajima, Kazufumi Hirano, Norikazu Yamada, Yutaka Okayama, Sanghun Iwashiro, Hideaki Maeda, Takanori Hayasaki, Toshiyuki Sunaya

Publikováno v: TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open, Vol 05, Iss 04, Pp e521-e532 (2021)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bb5ea6c535f8420d609fec71895615f
http://europepmc.org/articles/PMC8639284

Zobrazit plný text záznamu

Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings

Autor: Yoko Kidani, Satoshi Yamanaka, Jyoji Nakagawara, Yuji Murakawa, Toshiyuki Sunaya, Satoshi Ogawa, Takanari Kitazono, Takanori Ikeda, Shoichiro Sato, Yutaka Okayama, Susumu Miyamoto, Kazuo Minematsu, Sanghun Iwashiro

Publikováno v: Journal of Thrombosis and Thrombolysis

The approved dose of oral anticoagulant rivaroxaban for patients with non-valvular atrial fibrillation (NVAF) in Japan is 15 mg once daily (od) in patients whose creatinine clearance is ≥ 50 mL/min, but recent real-world studies have demonstrated t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dcf2b1a965d3ab2c39dba43f2e0ed3ff
https://doi.org/10.1007/s11239-019-01934-6

Zobrazit plný text záznamu

Long-term outcomes of Japan-specific dosage of rivaroxaban in high-risk patients with non-valvular atrial fibrillation: analysis from the XAPASS

Autor: K Minematsu, S Ogawa, Satoshi Yamanaka, Sanghun Iwashiro, Yutaka Okayama, Yasuhiro Hayashi, Takanari Kitazono, Toshiyuki Sunaya, Xapass investigators, Takanori Ikeda, Yuji Murakawa, Shoichiro Sato, J Nakagawara, Susumu Miyamoto

Publikováno v: European Heart Journal. 41

Background XAPASS is a real-world, prospective, single-arm, observational study conducted as a post-marketing surveillance mandated by the health authority in Japan. Nowadays, direct oral anticoagulant therapy using factor Xa or thrombin inhibitor ha

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f09a168a0847a7e25fd8185e4dfab7b
https://doi.org/10.1093/ehjci/ehaa946.0646

Zobrazit plný text záznamu

Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan

Autor: Susumu Miyamoto, Shoichiro Sato, Makiko Takeichi, Sanghun Iwashiro, Satoshi Ogawa, Yuji Murakawa, Kazuo Minematsu, Toshiyuki Sunaya, Takanari Kitazono, Satoshi Yamanaka, Takanori Ikeda, Yoko Kidani, Jyoji Nakagawara, Yutaka Okayama

Publikováno v: Journal of Stroke and Cerebrovascular Diseases. 29:104584

Background: It is important to understand the risk of thromboembolism and bleeding in patients with nonvalvular atrial fibrillation (NVAF) receiving direct oral anticoagulants; however, data on risk factors in Japanese patients are limited. Methods:

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ee4e8914f1beed0f788ceab358d3bb3
https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.104584

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání